Healthy SubjectsAIMANTNCT04645628
Optimization of the Acquisition Sequence to Improve the Quality and Comfort of Magnetic Resonance Imaging Exam
A study testing MRI examination in people with Healthy Subjects and Patient Performing an MRI Examination, run by Central Hospital, Nancy, France at 1 site in France.
Trial summary
The purpose of this study is to evaluate the optimization of MRI acquisition sequences. Read more about this study
- Who is it for?
- Ages 18 years and olderHealthy volunteers can take part
- Conditions the study is for
- Healthy Subjects, Patient Performing an MRI Examination
- What is being tested?
- MRI examination
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 720 participants
- Where
- 1 siteFrance
- Study dates
- 4 Dec 2020to 1 Dec 2028
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Who may be able to join
- to be over 18 year-old,
- to be able to understand the instructions given,
- to be enrolled in a social security plan,
- to have underwent a pre-inclusion medical examination,
- to give a written consent.
- to perform a MRI examination of the head, neck, spine, thorax, abdomen, pelvis, retroperitoneum, lower limbs, upper limbs or whole body during clinical follow-up care.
Who cannot join
- any contraindication to MR examination (active medical device, ferromagnetic foreign body, pregnancy, morbid obesity, claustrophobia, … ),
- subject under a measure of legal protection.
- to have a pathology in the anatomical area to be imaged
- to be employed by the CHRU of Nancy or having the slightest link of subordination with the CHRU of Nancy.
- to have a limited MRI examination time due to a sensitive clinical situation (sedation, unstable hemodynamic state, postoperative).
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
France1 site, 1 recruiting
- Recruiting
CHRU de Nancy
Nancy, 5400
Valerie Laurent, Md, PhD
About this study
The purpose of this study is to evaluate the optimization of MRI acquisition sequences.
- Being tested
- MRI examination
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
MRI examinationOther
All subjects (healthy subjects and patients) will have an MRI examination with optimized sequences
| Study group | Role | What they receive |
|---|---|---|
| All subjects will have an MRI examination | Experimental | Not described Receives: Other: MRI examination |
What is being measured
The primary outcome is the main question the study is designed to answer.
Image quality based on standard imaging quality criteria.
The image quality will be appreciated visually at least by a radiologist or a researcher.
Measured: 6 months after the last inclusion
Secondary outcomes (7)
Comparison of the Signal to Noise Ratio obtained by the optimized MRI sequence and the reference situation (standard sequence).
Signal to Noise Ratio will be measured in arbitrary units.
Measured: 6 months after the last inclusion
Comparison of the Contrast to Noise Ratio obtained by the optimized MRI sequence and the reference situation (standard sequence).
Contrast to Noise Ratio will be measured in arbitrary units.
Measured: 6 months after the last inclusion
Comparison of the acquisition time obtained with the optimized MRI sequence and the reference situation (standard sequence).
Time acquisition will be evaluated in minutes.
Measured: 6 months after the last inclusion
Comparison of blurring and artefacts obtained by the optimized MRI sequence and the reference situation (standard sequence).
Absence of blurring and artefacts will be assessed by at least one radiologist according to an ordinal scale.
Measured: 6 months after the last inclusion
Comparison of the spatial resolution obtained by the optimized MRI sequence and the reference situation (standard sequence).
Spatial resolution will be measured in mm².
Measured: 6 months after the last inclusion
Qualification of the MRI acquisition for a clinical study.
Validation of MRI acquisition by a centralized review center.
Measured: 6 months after the inclusion
Evaluation of intra-subject reproducibility on the same MRI and on two MRIs.
Measurement of intra-subject reproducibility on the same MRI and on two MRIs by the intra-class correlation coefficient for quantitative measurement or by the kappa coefficient for a qualitative measurement.
Measured: 6 months after the last inclusion
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted27 Nov 2020
- Study start4 Dec 2020
- Primary completion8 Dec 2027 (estimated)
- Study completion1 Dec 2028 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (6)Papers the sponsor has linked to this study.
- Other trials for Healthy SubjectsStudies of the same condition, open and under way.
- More trials run by Central Hospital, Nancy, FranceThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Other
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 720 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Central Hospital, Nancy, France
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Valérie LAURENT, Central Hospital, Nancy, France
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT04645628
- Sponsor's protocol ID
- 2020-A01969-30
- Acronym
- AIMANT
- Status last verified
- Mar 2026
- First submitted
- 16 Nov 2020
- Last updated
- 4 Mar 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Publications
He Z, Soullie P, Lefebvre P, Ambarki K, Felblinger J, Odille F. Changes of in vivo electrical conductivity in the brain and torso related to age, fat fraction and sex using MRI. Sci Rep. 2024 Jul 12;14(1):16109. doi: 10.1038/s41598-024-67014-9.
PubMed 38997324Caron B, Laurent V, Odille F, Danese S, Hossu G, Peyrin-Biroulet L. New magnetic resonance imaging sequences for fibrosis assessment in Crohn's disease: a pilot study. Scand J Gastroenterol. 2022 Dec;57(12):1450-1453. doi: 10.1080/00365521.2022.2094727. Epub 2022 Sep 29.
PubMed 36173349Boubaker F, Lane JI, Puel U, Drouot G, Witte RJ, Ambarki K, Gondim-Teixeira PA, Blum A, Parietti-Winkler C, Vallee JN, Gillet R, Eliezer M. High-Resolution 3T MRI of the Membranous Labyrinth Using Deep Learning Reconstruction. AJNR Am J Neuroradiol. 2026 Mar 4;47(3):723-729. doi: 10.3174/ajnr.A8989.
PubMed 40876943Gillet R, Boubaker F, Clara M, Ambarki K, Stemmer A, Drouot G, Gillet P, Gondim Teixeira PA, Blum A. Optimizing knee MRI: 3D proton density turbo spin echo nDixon sequence vs. 2D high-resolution turbo spin echo in half the acquisition time. Eur J Radiol. 2026 Feb;195:112552. doi: 10.1016/j.ejrad.2025.112552. Epub 2025 Nov 19.
PubMed 41285050Wary P, Hossu G, Ambarki K, Nickel D, Arberet S, Oster J, Orry X, Laurent V. Deep learning HASTE sequence compared with T2-weighted BLADE sequence for liver MRI at 3 Tesla: a qualitative and quantitative prospective study. Eur Radiol. 2023 Oct;33(10):6817-6827. doi: 10.1007/s00330-023-09693-y. Epub 2023 May 16.
PubMed 37188883Paillart G, He Z, Romero G, Ferry P, Ambarki K, Soullie P, Felblinger J, Odille F. Improved Radiofrequency Safety Modelling in MRI Using In Vivo Measurements of Brain Conductivity. NMR Biomed. 2026 Aug;39(8):e70335. doi: 10.1002/nbm.70335.
PubMed 42338094
Study at a glance
From the registry record, last updated by the sponsor on 4 Mar 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Optimization of the Acquisition Sequence to Improve the Quality and Comfort of Magnetic Resonance Imaging Exam
- ClinicalTrials.gov ID
- NCT04645628
- Acronym / sponsor ID
- AIMANT / 2020-A01969-30
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 720 participants (estimated)
- Lead sponsor
- Central Hospital, Nancy, FranceUniversity, hospital or other
- Study start
- 4 Dec 2020 (actual)
- Primary completion
- 8 Dec 2027 (estimated)
- Study completion
- 1 Dec 2028 (estimated)
- First posted
- 27 Nov 2020 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The purpose of this study is to evaluate the optimization of MRI acquisition sequences.
Study design
- Primary purpose
- Other
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| All subjects will have an MRI examination | Experimental | Other: MRI examination |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (6 listed)
- to be over 18 year-old,
- to be able to understand the instructions given,
- to be enrolled in a social security plan,
- to have underwent a pre-inclusion medical examination,
- to give a written consent.
Key exclusion criteria (5 listed)
- any contraindication to MR examination (active medical device, ferromagnetic foreign body, pregnancy, morbid obesity, claustrophobia, … ),
- subject under a measure of legal protection.
- to have a pathology in the anatomical area to be imaged
- to be employed by the CHRU of Nancy or having the slightest link of subordination with the CHRU of Nancy.
- to have a limited MRI examination time due to a sensitive clinical situation (sedation, unstable hemodynamic state, postoperative).
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| MRI examinationAll subjects (healthy subjects and patients) will have an MRI examination with optimized sequences | Other | All subjects will have an MRI examination |
Primary outcome
Image quality based on standard imaging quality criteria.
Time frame: 6 months after the last inclusion
The image quality will be appreciated visually at least by a radiologist or a researcher.
7 secondary outcomes
Comparison of the Signal to Noise Ratio obtained by the optimized MRI sequence and the reference situation (standard sequence).
Time frame: 6 months after the last inclusion
Comparison of the Contrast to Noise Ratio obtained by the optimized MRI sequence and the reference situation (standard sequence).
Time frame: 6 months after the last inclusion
Comparison of the acquisition time obtained with the optimized MRI sequence and the reference situation (standard sequence).
Time frame: 6 months after the last inclusion
Comparison of blurring and artefacts obtained by the optimized MRI sequence and the reference situation (standard sequence).
Time frame: 6 months after the last inclusion
Comparison of the spatial resolution obtained by the optimized MRI sequence and the reference situation (standard sequence).
Time frame: 6 months after the last inclusion
Qualification of the MRI acquisition for a clinical study.
Time frame: 6 months after the inclusion
Evaluation of intra-subject reproducibility on the same MRI and on two MRIs.
Time frame: 6 months after the last inclusion
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 4 Mar 2026.
- Results publication: PubMed 38997324He Z, Soullie P, Lefebvre P, Ambarki K, Felblinger J, Odille F. Changes of in vivo electrical conductivity in the brain and torso related to age, fat fraction and sex using MRI. Sci Rep. 2024 Jul 12;14(1):16109. doi: 10.1038/s41598-024-67014-9.
- Results publication: PubMed 36173349Caron B, Laurent V, Odille F, Danese S, Hossu G, Peyrin-Biroulet L. New magnetic resonance imaging sequences for fibrosis assessment in Crohn's disease: a pilot study. Scand J Gastroenterol. 2022 Dec;57(12):1450-1453. doi: 10.1080/00365521.2022.2094727. Epub 2022 Sep 29.
- Results publication: PubMed 40876943Boubaker F, Lane JI, Puel U, Drouot G, Witte RJ, Ambarki K, Gondim-Teixeira PA, Blum A, Parietti-Winkler C, Vallee JN, Gillet R, Eliezer M. High-Resolution 3T MRI of the Membranous Labyrinth Using Deep Learning Reconstruction. AJNR Am J Neuroradiol. 2026 Mar 4;47(3):723-729. doi: 10.3174/ajnr.A8989.
- Results publication: PubMed 41285050Gillet R, Boubaker F, Clara M, Ambarki K, Stemmer A, Drouot G, Gillet P, Gondim Teixeira PA, Blum A. Optimizing knee MRI: 3D proton density turbo spin echo nDixon sequence vs. 2D high-resolution turbo spin echo in half the acquisition time. Eur J Radiol. 2026 Feb;195:112552. doi: 10.1016/j.ejrad.2025.112552. Epub 2025 Nov 19.
- Results publication: PubMed 37188883Wary P, Hossu G, Ambarki K, Nickel D, Arberet S, Oster J, Orry X, Laurent V. Deep learning HASTE sequence compared with T2-weighted BLADE sequence for liver MRI at 3 Tesla: a qualitative and quantitative prospective study. Eur Radiol. 2023 Oct;33(10):6817-6827. doi: 10.1007/s00330-023-09693-y. Epub 2023 May 16.
- Derived from this study: PubMed 42338094Paillart G, He Z, Romero G, Ferry P, Ambarki K, Soullie P, Felblinger J, Odille F. Improved Radiofrequency Safety Modelling in MRI Using In Vivo Measurements of Brain Conductivity. NMR Biomed. 2026 Aug;39(8):e70335. doi: 10.1002/nbm.70335.
Related trials for Healthy Subjects
Recruiting
Colon-delivered Riboflavin and Gut Microbiota Composition
Microbiome Dysbiosis, Gut Health
Not yet recruiting
Neuroergonomic Analysis of a Brain-Computer Interface Device (BCI)
Healthy Volunteers - Male and Female
RecruitingPhase 1
First-in-Human Trial to Assess REGN20423 in Healthy Adult Participants and Adult Participants With Atopic Dermatitis
Healthy Volunteer, Atopic Dermatitis
Not yet recruitingObservational study
Establishment of Biobank of Nasal Epithelium Samples From Healthy Volunteers
Healthy
RecruitingObservational study
Improved Methods of Cell Selection for Bone Marrow Transplant Alternatives
Graft-Versus-Host Disease, Graft-versus-leukemia
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing MRI examination in people with Healthy Subjects and Patient Performing an MRI Examination, run by Central Hospital, Nancy, France at 1 site in France.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 6 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 4 Mar 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in France. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Valérie LAURENT, MD, PhD (+33383154181, v.laurent@chru-nancy.fr), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Image quality based on standard imaging quality criteria. (time frame: 6 months after the last inclusion). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT04645628, which also lists 6 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 4 Mar 2026.